跳至主要内容

Medicilon 20th Anniversary - Keep pace with the times in innovation, thanks for having you

 Medicilon 20th.webp

In 2024, Medicilon will celebrate its 20th anniversary.  At the time of departure, Medicilon shouldered the dream of China's new drug research and development, took root in Zhangjiang, Shanghai, and embarked on a long journey to pursue the dream.  During the past 20 years, Medicilon has transformed into a leading one-stop biopharmaceutical preclinical R&D service CRO in China, and is moving forward with its goal of being a world-class CRO.

From chemical drugs to bi/multi-specific antibodies, ADCs, nucleic acids, mRNA, PROTAC, CGT and other fields, Medicilon continue to move towards the forefront of technology.  From the initial provision of chemical services to one-stop biopharmaceutical preclinical R&D services, Medicilon continue to expand the services.  From 0 to 420 IND approvals, Medicilon helps customers complete new drug clinical trial applications from China NMPA, US FDA, EU EMEA and Australia TGA.  These include the world's first inhaled nanobody drug for the treatment of moderate to severe asthma, the world's first innovative drug targeting RNA helicase, the world's first dual-antibody ADC drug that completely knocks out fucose, the world's first CAR-raNK cell therapy, China's first ADC targeting folate receptor FRα, China's first potassium ion competitive acid blocker Keprasen tablets, China's first clinically approved STING agonist, China's first original highly selective EP4 receptor antagonist, China's first Muc1-ADC drug and more.

Medicilon collaborates with pharmaceutical companies to enable one-stop preclinical research and development of new drugs, collaborates with universities to promote in-depth integration of industry, academia and research, and collaborates with AI pharmaceutical companies to accelerate drug discovery and development.  The Medicilon Academician Innovative Drug Maturation Center has established a new drug investment and financing support platform to provide financial support for new drug research and development.  Furthermore, Medicilon has established a new drug research and development trading platform to facilitate the transformation and trading of new drug research and development stage results, thereby building a new drug empowerment ecosystem and promoting the integration and orderly development of industry, academia, research and finance.  This is the joining and companionship of fellows that gathers the strength to be at the forefront and the efforts and perseverance of fellows that drive China's biopharmaceutical to the world.

Medicilon is grateful for the era, grateful for exploration, and grateful for having you along the way.

标签：

评论

发表评论

此博客中的热门博文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites   On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services
发表评论
阅读全文

In Vitro Enzyme Activity Assay

  Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+  in vitro  enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...
发表评论
阅读全文

Pharmacokinetics Services

Pharmacokinetics Services Our pharmacokinetics department offers the clients a broad spectrum of high quality of services in the areas of in vitro ADME, in vivo pharmacokinetics and bioanalysis services, ranging from small molecules to large molecules, such as protein and antibody. The animal species involved in our services are non-human primate, canine, mice, rat, rabbit and hamster. Meanwhile, non-human primate experimental platform and isotope platform for protein/antibody are certified by the Shanghai government. Preclinical Pharmacokinetics Method development and validation (GLP,Non-GLP) Bioanalysis Pharmacokinetics (Tumor bearing rodents, Bioavailability, Crossover studies, Cassette (N in 1) dosing and analysis, effects of gender on pharmacokinetics, BBB penetration ) Stability in vehicles and plasma Drug interaction studies In vitro metabolic stability CYP 450 inhibition Plasma protein binding studies Distribution studies Excretion studies Prediction an...
发表评论
阅读全文